MANGOCEUTICALS, INC. Files 8-K: Material Agreement, Equity Sales
Ticker: MGRX · Form: 8-K · Filed: May 30, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | May 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
TL;DR
MANGOCEUTICALS, INC. signed a big deal and sold some stock on 5/15.
AI Summary
On May 15, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on May 30, 2025.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves a material definitive agreement and unregistered sales of equity, which can introduce financial and regulatory risks.
Key Numbers
- 001-41615 — SEC File Number (Identifies the company's filing history with the SEC.)
- 87-3841292 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- May 15, 2025 (date) — Date of Earliest Event Reported
- May 30, 2025 (date) — Filing Date
- Texas (location) — State of Incorporation
- Dallas (location) — Principal Executive Offices City
- 75248 (location) — Principal Executive Offices Zip Code
FAQ
What is the nature of the material definitive agreement entered into by MANGOCEUTICALS, INC. on May 15, 2025?
The filing indicates the entry into a material definitive agreement on May 15, 2025, but the specific details of this agreement are not provided in the excerpt.
What type of equity securities were sold in the unregistered sales reported by MANGOCEUTICALS, INC.?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not detailed in the provided text.
What are the key financial statements and exhibits being filed with this 8-K?
The filing states that financial statements and exhibits are included, but the specific content of these documents is not detailed in the excerpt.
When was MANGOCEUTICALS, INC. incorporated and in which state?
MANGOCEUTICALS, INC. was incorporated in Texas.
What is the principal executive office address for MANGOCEUTICALS, INC.?
The principal executive offices of MANGOCEUTICALS, INC. are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas, 75248.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding MANGOCEUTICALS, INC. (MGRX).